EA201992319A1 - Анти-cd33 антитела и способы их применения - Google Patents
Анти-cd33 антитела и способы их примененияInfo
- Publication number
- EA201992319A1 EA201992319A1 EA201992319A EA201992319A EA201992319A1 EA 201992319 A1 EA201992319 A1 EA 201992319A1 EA 201992319 A EA201992319 A EA 201992319A EA 201992319 A EA201992319 A EA 201992319A EA 201992319 A1 EA201992319 A1 EA 201992319A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- ways
- compositions
- application
- epitopes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Настоящее изобретение в целом относится к композициям, которые содержат антитела, например моноклональные, химерные, гуманизированные антитела, фрагменты антител и т.д., которые специфически связывают один или более эпитопов в белке CD33, например человеческом CD33 или CD33 млекопитающих, и имеют улучшенные и/или усиленные функциональные характеристики, и к применению таких композиций в профилактике, снижении риска или лечении пациента.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862667388P | 2018-05-04 | 2018-05-04 | |
PCT/US2018/045056 WO2019028283A1 (en) | 2017-08-03 | 2018-08-02 | ANTI-CD33 ANTIBODIES AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201992319A1 true EA201992319A1 (ru) | 2020-03-25 |
Family
ID=69942823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992319A EA201992319A1 (ru) | 2018-05-04 | 2018-08-02 | Анти-cd33 антитела и способы их применения |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201992319A1 (ru) |
-
2018
- 2018-08-02 EA EA201992319A patent/EA201992319A1/ru unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502463A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
WO2016201388A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
WO2016201389A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
EA201791127A1 (ru) | Антитела, содержащие модифицированные константные участки тяжелой цепи | |
PH12021550041A1 (en) | Anti-sortilin antibodies and methods of use thereof | |
EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
EA202190235A1 (ru) | Антитела к cd33 и способы их применения | |
EA202091747A1 (ru) | Составы антитела b7-h4 | |
EA202090791A1 (ru) | Агонистические антитела против cd40 | |
MX2023011121A (es) | Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos. | |
EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
MX2021015212A (es) | Anticuerpos antisortilina para uso en terapia. | |
EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
EA202092595A1 (ru) | Антитела к siglec-7 и способы их применения | |
MX2022007156A (es) | Metodos de uso de anticuerpos anti-cd33. | |
EA201992319A1 (ru) | Анти-cd33 антитела и способы их применения | |
EA201992324A1 (ru) | Анти-trem2 антитела и способы их применения |